Form 4: Intra-Cellular Therapies SVP of Finance, CFO Lawrence J. Hineline, Reports Acquisition of Restricted Stock Units

Lawrence J. Hineline, SVP of Finance and CFO of Intra-Cellular Therapies, Inc., reports the acquisition of 26,227 restricted stock units on March 1, 2024.

Summary

• On March 5, 2024, Lawrence J. Hineline, the SVP of Finance and CFO of Intra-Cellular Therapies, Inc., filed a Form 4 with the SEC.
• The filing reports that on March 1, 2024, Mr. Hineline was granted 26,227 restricted stock units (RSUs).
• These RSUs represent a contingent right to receive one share of common stock each.
• The RSUs vest in three equal annual installments, starting on the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, and the sentiment is neutral. It reflects routine executive compensation practices.

Positives

• The grant of restricted stock units to a key executive aligns their interests with those of the shareholders, potentially incentivizing performance and long-term value creation.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date, suggesting a multi-year commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry.

Key Dates